LAQV, REQUIMTE, Department of Chemical Sciences, FFUP, Rua Jorge Viterbo Ferreira n.º 228, 4050-313, Porto, Portugal.
School of Medicine and Biomedical Sciences (ICBAS), University of Porto, Rua Jorge Viterbo Ferreira n.º 228, 4050-313, Porto, Portugal.
Sci Rep. 2023 Oct 4;13(1):16667. doi: 10.1038/s41598-023-43865-6.
Supplementing diets with rumen-protected lysine is a common strategy to meet the nutritional needs of high-producing dairy cows. This work addressed two separate but crucial issues: the lysine protection degree across the entire digestive tract as well as the production scalability of the proposed delivery systems. This was achieved by evaluating, in vitro or ex vivo, previously developed rumen-resistant lipid nanoparticles regarding their stability in the digestive tract and in the bloodstream of the dairy cow as well as how their production could be scaled-up. Results showed that the developed nanoparticles were able to resist digestion along the digestive tract but were degraded in the blood over 24 h. Thus, releasing their content to be used by the animal. In vitro viability assays were also performed, with the nanoparticles being found not to be inherently toxic when using nanoparticle concentrations up to 1 mg/mL. Results showed that neither the purity of the used lipids nor the production method significantly altered the nanoparticles' properties or their ruminal resistance. Furthermore, the shelf-life of these nanoparticles was assessed, and they were found to retain their properties and remain usable after at least 1 month of storage. Moreover, a pilot-scale production allowed the production of nanoparticles with similar properties to the previous ones made using standard methods. To summarize, the proposed rumen-resistant nanoparticles presented potential as orally ingested lysine delivery systems for dairy cattle supplementation, being capable of a large-scale production using cheaper components while maintaining their properties and without any efficiency loss. It should however be noted that these results were obtained mainly in vitro and further in vivo bioavailability and production experiments are needed before this technology can be confirmed as a viable way of delivering lysine to dairy cows.
在日粮中添加包膜赖氨酸是满足高产奶牛营养需求的常用策略。本工作解决了两个独立但关键的问题:整个消化道的赖氨酸保护程度以及所提出的输送系统的生产可扩展性。这是通过评估先前开发的抗瘤胃脂质纳米粒在消化道和奶牛血液中的稳定性及其生产的可扩展性来实现的。结果表明,所开发的纳米粒能够抵抗消化道的消化,但在血液中会在 24 小时内降解,从而释放其内容物供动物使用。还进行了体外存活能力测定,结果表明,使用高达 1mg/mL 的纳米粒浓度时,纳米粒本身没有毒性。结果表明,所使用的脂质的纯度和生产方法都不会显著改变纳米粒的性质或其抗瘤胃能力。此外,还评估了这些纳米粒的保质期,结果发现它们在至少 1 个月的储存后仍保留其性质并保持可用。此外,中试规模的生产允许使用类似的生产方法生产具有类似性质的纳米粒。总之,所提出的抗瘤胃纳米粒具有作为奶牛口服赖氨酸输送系统的潜力,能够使用更便宜的成分进行大规模生产,同时保持其性质,并且没有任何效率损失。然而,应当指出,这些结果主要是在体外获得的,在该技术被确认为向奶牛输送赖氨酸的可行方法之前,还需要进行进一步的体内生物利用度和生产实验。